Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis

BACKGROUND: In Crohn’s disease and ulcerative colitis, the anti-α4β7 integrin antibody vedolizumab has demonstrated efficacy in phase III trials and has been successfully used under real-world conditions. Occasionally, it has also been used in other forms of inflammatory bowel disease (IBD) such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Besendorf, Laura, Müller, Tanja M., Geppert, Carol-Immanuel, Schneider, Ines, Mühl, Laura, Atreya, Imke, Vitali, Francesco, Atreya, Raja, Neurath, Markus F., Zundler, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244938/
https://www.ncbi.nlm.nih.gov/pubmed/35784193
http://dx.doi.org/10.1177/17562848221098899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244938/
https://www.ncbi.nlm.nih.gov/pubmed/35784193
http://dx.doi.org/10.1177/17562848221098899

Ejemplares similares